SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. It will generate domestically produced bitcoin powered by nuclear, hydro, and solar energy. It operates through the Digital Asset Mining and HPC Leasing segments. The company was founded by Paul B. Prager and Nazar M. Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulfs expanded Kentucky Power agreement, which doubles contracted capacity at its Muskie campus to 1 GW and advances the planned second phase, is fueling discussion of its AI/HPC data-center expansion. Bulls see the added capacity as support for the growth thesis, while bears point to the share-price decline and concerns about execution, capital spending and financing; the agreement remains subject to regulatory approval.

Chipotle Mexican Grill, Inc. engages in the business of developing and operating restaurants that serve a relevant menu of burritos, burrito bowls, quesadillas, tacos, and salads made using fresh, high-quality ingredients. The company was founded by Steve Ells in 1993 and is headquartered in Newport Beach, CA.

Chipotle Mexican Grill

A sharp selloff has traders pointing to weakness across restaurant stocks and worries about cautious consumers, affordability, and Chipotles food quality and portions; many are asking for a clear company-specific explanation. Unconfirmed takeover speculation is also circulating, with some traders anticipating a bid and others dismissing the chatter as a pump-and-dump rumor.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

OpenAI CEO Sam Altmans description of Cerebras as a close partner has eased concerns after reports said OpenAIs latest Ultrafast model uses Nvidia GPUs, prompting a rebound in CBRS shares. Bulls view the comment as reassurance about the partnership, while skeptics note it does not confirm Cerebras powers that model and point to ongoing insider share unlocks and selling pressure.

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

A sharp rally and breakout-focused trading have fueled attention, with bulls pointing to call activity, short-squeeze potential and Musks discussions with TSMC about Terafab; skeptics counter that the valuation is stretched and share unlocks could add selling pressure.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

New 24-month HOPE-3 open-label extension data for Capricors Duchenne therapy deramiocel, including a reported 76% slowing of upper-limb decline after placebo patients switched to treatment, has refocused attention on the amended BLA ahead of the FDAs November 22 decision. Bulls say the results strengthen the approval case, while skeptics point to the open-label design, unresolved FDA concerns and uncertainty over the analysis; the positive data has coincided with volatile, disappointing price action and debate over short selling.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

A cluster of open-market insider purchases led by CEO Ryan Cohen is drawing attention as GameStop shares rise and traders discuss a possible technical breakout. Bulls see the buying and approaching warrant expiry as potential fuel for more momentum or short covering, while skeptics argue the purchases need to be followed by substantive company news.

Velo3D, Inc. operates as a technology company, which engages in developing and manufacturing metal laser sintering printing machines for 3D printing. Its products include assure system, flow software, sapphire printer & sapphire XC. The company was founded by Benyamin Buller in June 2014 and is headquartered in Fremont, CA.

Velo3D Inc

VELOs selloff is drawing attention to CFO James Suvas sudden departure after a short tenure and the limited explanation for it, prompting concerns about management transparency and the companys financial outlook. Some traders view the appointment of an interim CFO as continuity or the market reaction as overblown, while claims of a short attack remain speculation.

Vistra Corp. is a holding company, which engages in the provision of electricity and power generation. It operates through the following segments: Retail, Texas, East, West, and Asset Closure. The Retail segment includes sale of electricity and natural gas to residential, commercial, and industrial customers. The Texas and East segments are involved in electricity generation, wholesale energy sales and purchases, commodity risk management activities, fuel production and fuel logistics management. The West segment represents the company's electricity generation operations in CAISO. The Asset Closure segment refers to the decommissioning and reclamation of retired plants and mines. The company was founded in 1882 and is headquartered in Irving, TX.

Vistra Corp

Reports of a federal loan package to fund upgrades at Vistras nuclear plants are driving attention, with traders linking the added capacity to rising AI and data-center power demand. Many view the plan as bullish, while others question the muted, volatile price reaction; the financing remains a reported plan rather than a completed loan.

Vaxcyte, Inc. engages in the development of vaccines for infectious diseases. It focuses on conjugate vaccines and protein-based vaccines developed through the Sutro Biopharma's Xpress CF Platform, a cell-free protein synthesis technology. The company was founded by Grant E. Pickering and Jeff Fairman on November 27, 2013, and is headquartered in San Carlos, CA.

Vaxcyte Inc

Vaxcyte shares are surging after VAX-31 met all primary endpoints in the Phase 3 OPUS-1 trial, with traders highlighting results against existing pneumococcal vaccines. The sharp move has prompted profit-taking and short bets, while some investors cite dilution and cash-burn risks despite the positive trial data.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

A Bank of America upgrade to Buy, citing potential upside from DraftKings prediction-market business, is driving attention. Traders are split over whether DKeX can grow into a meaningful opportunity or will struggle against Kalshi and Polymarket amid regulatory uncertainty, with many still bearish after the stocks steep decline.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

VKTX Stock On Track To Beat LLY, NVO This Month After Obesity Drug Data — Can Viking Win Over Wegovy And Zepbound Users?

Equity

Obesity specialist Lou Aronne said switching from a GLP-1 drug to a dual GLP-1/GIP drug could mean greater weight loss.

VKTX, GPCR, ALT Stocks Rise: Novo Nordisk Signals Bigger M&A As It Chases Over 5 ‘Multi-Blockbusters’

Novo targets over $23 billion in risk-adjusted pipeline sales by 2035, excluding any contribution from future acquisitions.

Why Is Altimmune (ALT) Up 14.2% Since Last Earnings Report?

Altimmune (ALT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Is Altimmune Worth Buying as Cash Rises but Execution Risks Linger?

ALT's stronger cash position supports pemvidutide's MASH, AUD and ALD programs, but long timelines, funding needs and competition remain risks.

Altimmune's Phase III MASH Study Puts 2029 Data in Investor Focus

ALT has moved pemvidutide into Phase III MASH testing, with supportive mid-stage data, regulatory backing and a 2029 readout ahead.

Kodiak's Q2 Loss Wider Than Expected, Pipeline Development in Focus

KOD's Zenkuda advances toward regulatory submission as its pipeline gains momentum. Key clinical data is expected later in 2026.

ALT's Q2 Loss Narrower Than Expected, Pemvidutide's Studies in Focus

Altimmune posts a narrower Q2 loss. Its $519M in cash supports operations into 2029, while pemvidutide advances across liver and AUD studies.



BLTE Stock Rises as FDA Grants Priority Review to Tinlarebant NDA

Belite Bio's tinlarebant wins FDA priority review for Stargardt Disease, with a decision expected in February 2027 after positive phase III data.

KOD Begins Late-Stage Study of KSI-501 in Diabetic Macular Edema

Kodiak launches a global phase III study of KSI-501 in DME, testing its dual IL-6 and VEGF approach for durable disease control.

PBYI Q2 Earnings & Sales Beat Estimates, 2026 Guidance Raised

Puma Biotechnology tops Q2 earnings and revenue estimates, raises its 2026 guidance, and outlines upcoming alisertib study milestones as Nerlynx sales climb.

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. Its lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Altimmune Inc

Neutral Sentiment

Up more than 1% 

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be this week?

Stocktwits

Stocktwits Polls

Investors are closely watching management's promises of non-dilutive funding for AUD Phase 3 trials to avoid further share price dilution.

Long-term holders remain split on whether Big Pharma will strike an acquisition deal now or wait for more clinical validation.

High short interest figures and heavy dark pool activity have bulls convinced a potential violent upward reversal is building.

Debate persists over whether leadership's recent move to New Jersey and administrative hires are strategic positioning or simple corporate self-interest.

The stock's valuation is being measured against a broad pipeline including MASH, AUD, and ALD, leading some to call it severely undervalued.

Feed

News

Sentiment

Earnings

Fundamentals

Info

ALT News